September 13, 2021 | Daily JAM, Jubak Picks, Top 50 Stocks, Volatility |
Back on September 4 I posted a video on YouTube and this site “September and October 2021 Worse Than Usual for Investors?” that argued that September, the worst performing month for the Standard & Poor’s 500 from 1950 through 2020, and October, historically the home of the biggest one-day or one-week stock market crashes, stood a good change of being even worse than usual this year. I cited factors such as the Fed’s September 22 monetary policy meeting, a potential stalemate over the raising the debt ceiling, and economic uncertainty created by the Delta Variant (see last weeks weak jobs report as evidence on that front) as reasons for thinking that we could see a repeat of the historical weakness and volatility this September and October–but with a bit of supercharging. I don’t want to revisit all the reasons I gave in that video–Hey, just watch it, ya know?–but let me add a couple of points that I didn’t mention in the video. Like the effects of the continued shortage of chips on car manufacturers and hence car sales. Like the run-off in federal Pandemic economic help that’s now scheduled for this fall. Like signs of weakness in consumer sentiment and business confidence. Instead of more on “the problem” lets talk about potential solutions- the “what should I do stuff.”
February 2, 2021 | Daily JAM, Morning Briefing, Short Term |
As of 3:15 p.m. today, February 2, in New York, shares of GameStop (GME)were down 56.22% to $98.50. That a big drop from the January 27 closing high of $347.51, but it’s still significantly above the $17.25 price on January 4. Other stocks that have ridden the Reddit WallStreetBets fever for short squeeze horses are down today too. AMC (AMC) is off 39.70% to $8.02. First Majestic Silver (AG), the big silver play of the last few days, has given up 24.28% to $16.75. Bed Bath & Beyond (BBBY) is off 14.64% to $25.77. American Airlines (AAL), an early short squeeze play, slipped 1.16% to $17.65. The only potential short squeeze bet (if it was, that is) that’s still climbing is vaccine pill biotech Vaxart (VXRT), which was up 34.30% at 3:15 and looks to be riding momentum into the close. (The shares were up 54.43% as of 3:40 p.m.) Vaxart does bring this question to mind: So if the money is coming out of GameStop, etc., where is it going?
January 10, 2021 | Daily JAM |
The big JPMorgan Chase healthcare conference that began today, January 10, and that runs for the rest of this week, will keep biotech stock prices moving up even as valuations in the sector look increasingly stretched.
July 7, 2020 | ACAD, Daily JAM, Stock Alerts |
 Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock...
June 3, 2020 | Daily JAM |
As I wrote in my previous post this morning, I like the upward momentum in the biotech sector resulting from the race for a coronavirus vaccine and treatment and the cash flows into the sector from investors and big drug companies such as Pfizer (PFE.) That has pushed...
March 6, 2018 | ACAD, Daily JAM, Stock Alerts |
Today I'm selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective for...
February 27, 2017 | Daily JAM, Stock Alerts |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
February 3, 2017 | Uncategorized |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
January 9, 2017 | ACAD, Daily JAM, INCY, IONS, Morning Briefing |
JPMorgan Chase holds its big biotech conference today, Monday January 9, and last week’s momentum in the sector as well as likely upbeat guidance to begin the conference at 10:30 a.m. Eastern time from Celgene (CELG) should have the sector on the move.
January 4, 2017 | Daily JAM, Stock Alerts |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
November 15, 2016 | ACAD, Daily JAM, Stock Alerts |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
November 14, 2016 | ACAD, BMY, Daily JAM, INCY, OGXI |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...